ARO-HSD is under clinical development by Arrowhead Pharmaceuticals and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect ARO-HSD’s likelihood of approval (LoA) and phase transition for Non-Alcoholic Steatohepatitis (NASH) took place on 23 Dec 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their ARO-HSD Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

ARO-HSD overview

ARO-HSD is under development for the treatment of nonalcoholic steatohepatitis. The drug candidate is developed based on TRiM platform using Dynamic polyconjugate (DPC) delivery system. It acts by targeting HSD17B13. It is administered through subcutaneous route.

Arrowhead Pharmaceuticals overview

Arrowhead Pharmaceuticals (Arrowhead), formerly Arrowhead Research, is a pharmaceutical company. It develops and markets medicinal products including ARO-AAT, JNJ-3989, ARO-APOC3, ARO-ANG3, ARO-ENaC, ARO-HIF2, ARO-Lung2, ARO-HSD, ARO-HIF2, AMG 890, ARO-JNJ1, ARO-JNJ2 and ARO-JNJ3.The company develops pipeline drugs that are being developed to treat chronic hepatitis B infection for the treatment of liver disease, cardiovascular disease, hypertriglyceridemia, dyslipidemia, cystic fibrosis and and renal cell carcinoma. It also offers design of internal preclinical and clinical development programs to enable novel new therapies. The company has operations in California and Wisconsin, the US. Arrowhead is headquartered in Pasadena, California, the US.

Quick View ARO-HSD LOA Data

Report Segments
  • Innovator
Drug Name
  • ARO-HSD
Administration Pathway
  • Subcutaneous
Therapeutic Areas
  • Gastrointestinal
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.